Women with genetic mutations fare no worse with breast or ovarian cancer, study finds

October 1, 2021 12:00 am

By Krista Conger

Newly diagnosed breast or ovarian cancer patients who carry common cancer-associated mutations have similar or better short-term survival rates than those with no mutations, researchers report.

Women newly diagnosed with breast or ovarian cancer who are also … Read more

Researchers pinpoint how PARP inhibitors combat BRCA1 and BRCA2 tumor cells

August 13, 2021 9:27 pm

A team of Massachusetts General Hospital (MGH) researchers has discovered how an important class of anti-cancer drugs called PARP inhibitors works, a finding that could help improve treatment and prolong survival for patients with breast cancer and other malignancies.… Read more

Old Antibiotic Targets BRCA-Mutated, PARP Inhibitor-Resistant Tumors

June 18, 2021 12:21 pm

Studies in laboratory cell lines and in mouse tumor models show an antibiotic developed in the 1950s called novabiocin effectively targets and kills cancer cells with abnormal BRCA1 or BRCA2 genes, which normally help to repair damaged DNA.… Read more

Universal Genetic Testing Is Far From a Reality in Patients With Ovarian Cancer

June 8, 2021 11:28 am

by Victoria Forster, PhD

Rates of genetic testing in ovarian cancer “remain well below the goal of universal testing,” according to authors of a systematic review and meta-analysis published in Gynecologic Oncology.1Read more

ARIEL2 Analysis Sheds Light on Biomarkers of Response to Rucaparib in Ovarian Cancer

May 4, 2021 2:00 pm

RAD51C and RAD51D mutations and high-level BRCA1 promotor methylation are predictive of response to rucaparib in patients with recurrent ovarian cancer, while genomic scars linked with homologous recombination deficiency is predictive of response only in those with platinum-sensitive disease.

By … Read more

PARP Inhibitor Tops Chemo for Recurrent BRCA Ovarian Cancer

March 20, 2021 4:00 pm

Modest improvement in PFS with rucaparib but worse outcome for reversion mutation.

By Charles Bankhead

A PARP inhibitor slowed progression of recurrent, advanced BRCA-positive ovarian cancer as compared with standard chemotherapy, a randomized trial showed.

Treatment with rucaparib (Rubraca) … Read more

How Biomarker Testing May Help Women Battling Ovarian Cancer

February 18, 2021 6:00 pm

Receiving a cancer diagnosis can be overwhelming. But the more you know about your specific situation, the better.

By

Every year, more than 21,000 women in the United States are diagnosed with ovarian cancer. In about half of

Read more

Proton Therapy Induces Biologic Response to Attack Treatment-Resistant Cancers

February 17, 2021 4:00 pm

Mayo Clinic researchers have developed a novel proton therapy technique to more specifically target cancer cells that resist other forms of treatment. The technique is called LEAP, an acronym for “biologically enhanced particle therapy.” The findings are published today in … Read more

Common Genetic Test Often Wrong When Identifying Rare Disease-Causing Variants Such as BRCA1 and BRCA2, Study Says

February 16, 2021 10:00 am

By Sandee LaMotte, CNN

A genetic test used to detect common traits many people share is not reliable in identifying rare disease-causing variations, such as those that can predict breast and ovarian cancer, a new study has found.

The SNP … Read more

Triple therapy Shows Promise in Non-Germline BRCA-Mutated Ovarian Cancer

October 10, 2020 5:00 pm

By Savannah Demko

Triple therapy with olaparib plus durvalumab and bevacizumab were well-tolerated in patients with non-germline BRCA-mutated, platinum-sensitive, relapsed ovarian cancer, according to data presented at ESMO Virtual Congress 2020.

“Preclinical studies suggest the potential for synergy between … Read more

Bayer’s ATR Inhibitor May Benefit Cancers With ATM Aberrations, Early Data Suggest

September 29, 2020 4:00 pm

Researchers are optimistic that data from a first-in-human clinical trial of Bayer’s ATR-inhibiting agent, BAY-1895344, may pave the way for a new class of precision oncology treatments for patients with certain DNA damage response (DDR) defects in their tumors.

The … Read more

Why Some Cancers May Respond Poorly to Key Drugs Discovered

September 22, 2020 4:00 pm

Patients with BRCA1/2 mutations are at higher risk for breast, ovarian and prostate cancers that can be aggressive when they develop—and, in many cases, resistant to lifesaving drugs. Now scientists at The University of Texas at Austin and Ajou University … Read more

Olaparib Improves Median Time Without Disease Progression in BRCAm Ovarian Cancer

September 18, 2020 3:00 pm

Olaparib (Lynparza®; AstraZeneca/Merck & Co.*) has demonstrated a long-term progression-free survival (PFS) benefit versus placebo as a 1st-line maintenance treatment in patients with newly diagnosed, advanced BRCA-mutated (BRCAm) ovarian cancer who had a complete or partial response … Read more

Patient-Reported Outcomes for Rucaparib as a Maintenance Therapy in Recurrent Ovarian Cancer

September 3, 2020 5:00 pm

By Susan Moench, PhD, PA-C

Results of an exploratory analysis showed longer quality-adjusted progression-free survival (QA-PFS) and quality-adjusted time without symptoms or toxicity (Q-TWiST) in women with recurrent ovarian cancer treated with maintenance use of the poly(ADP-ribose) polymerase (PARP) inhibitor, … Read more

Universal BRCA Testing Could Prevent Countless Cancer Deaths

July 17, 2020 1:00 pm

By Diana Swift

Population screening found to be cost-effective for higher income countries

Screening entire populations of women for mutations in breast and ovarian cancer susceptibility genes could prevent hundreds of thousands of cases in the U.S., and millions globally, … Read more

Convenient Spit Test Helps Women Assess Cancer Risk From The Comfort Of Their Own Homes

June 1, 2020 4:00 pm

By Stand Up To Cancer

Genetic testing for cancer risk can significantly improve the prevention or treatment of hereditary cancers, but studies have shown that people who might have a genetic risk often don’t get tested. A collaborative Stand Up … Read more

New OS Data With Olaparib Support ‘New Era’ for Ovarian Cancer

May 14, 2020 10:00 am

By Liam Davenport

Women with platinum-sensitive relapsed ovarian cancer and a BRCA mutation could see their survival extended by over a year by maintenance therapy with the PARP-inihibitor olaparib (Lynparza, AstraZeneca).

The new overall survival (OS) data come … Read more

Research Suggests Statins Could Lower Ovarian Cancer Risk

February 18, 2020 10:00 am

By Cancer Research UK

A genetic study has found evidence to suggest that women who take statins in the long term could be less likely to develop ovarian cancer, according to new research funded by Cancer Research UK published today … Read more

ASCO Guideline: Germline Testing Recommended for All Women Diagnosed With Epithelial Ovarian Cancer

February 6, 2020 11:00 am

By Susan Moench, PhD, PA-C

A central tenant of a recently issued American Society of Clinical Oncology (ASCO) guideline is that all women with a diagnosis of epithelial ovarian cancer should be offered testing for specific germline mutations associated with … Read more

Olaparib Plus Durvalumab Show Durable Activity in Germline BRCA+ Breast, Ovarian Cancer

October 11, 2019 5:00 pm

By Wayne Kuznar

The case for the combination of olaparib (Lynparza) and durvalumab (Imfinzi) in patients with metastatic breast cancer and relapsed ovarian cancer with germline BRCA mutations was strengthened based on the updated results from the phase I/II MEDIOLA, … Read more